beta

ALKS

Alkermes Plc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Market Cap: 3.02 Billion

Primary Exchange: NASDAQ

Website: http://www.alkermes.com

Shares Outstanding: 159 Million

Float: 157 Million

Dividend: (%)

Beta: 0.830042718027354

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 1671 trading days

From: 2015-12-28 To: 2020-07-13

Lowest Point:

Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

via: PR Newswire at 2019-06-12 03:00:00:000

-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune Cells While Avoiding Activation of Immunosuppressive Cells -- DUBLIN , June 12… read more...

Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

via: PR Newswire at 2019-06-12 03:00:00:000

-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune Cells While Avoiding Activation of Immunosuppressive Cells -- DUBLIN , June 12… read more...

FDA Ad Com tomorrow on utility of higher-dose opioids

via: SeekingAlpha at 2019-06-10 13:06:51:000

The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...

FDA Ad Com tomorrow on utility of higher-dose opioids

via: SeekingAlpha at 2019-06-10 13:06:51:000

The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud